A Phase 1 Dose Escalation Study of VX-973 in Healthy Participants
- Registration Number
- NCT06615570
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Brief Summary
The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple doses of VX-973 in healthy participants.
- Detailed Description
This clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (That is, clinical trial information for this applicable clinical trial was submitted under section 402(j)(4)(A) of the Public Health Service Act and 42 CFR 11.60 and is not subject to the deadlines established by sections 402(j)(2) and (3) of the Public Health Service Act or 42 CFR 11.24 and 11.44.).
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 30
- Body mass index (BMI) of 18.0 to 32.0 kilogram per meter square (kg/m^2)
- A total body weight of more than (>) 50 kg
- Participants of non-childbearing potential
- Nonsmoker or ex-smoker for at least 3 months before screening
Key
- History of febrile illness or other acute illness that has not fully resolved within 14 days before the first dose of study drug
- Any condition possibly affecting drug absorption, distribution, metabolism, or excretion
Other protocol defined Inclusion/Exclusion criteria may apply.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SEQUENTIAL
- Arm && Interventions
Group Intervention Description Part A: Single Ascending Dose VX-973 Participants will be randomized to receive a single dose of VX-973 under fasted conditions. Part B: Multiple Ascending Dose VX-973 Participants will be randomized to receive multiple doses of VX-973 under fasted conditions. Placebo Part A Placebo Participants will be randomized to receive placebo matched to VX-973. Placebo Part B Placebo Participants will be randomized to receive placebo matched to VX-973.
- Primary Outcome Measures
Name Time Method Part B: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) From Day -1 up to Day 85 Part A: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) From Day -1 up to Day 30
- Secondary Outcome Measures
Name Time Method Part B: Maximum Observed Plasma Concentration (Cmax) of VX-973 From Day 1 up to Day 85 Part A: Area Under the Concentration Versus Time Curve (AUC) of VX-973 From Day 1 up to Day 30 Part B: Area Under the Concentration Versus Time Curve (AUC) of VX-973 From Day 1 up to Day 85 Part A: Time Taken for VX-973 to Reach Maximum Concentration (tmax) From Day 1 up to Day 30 Part A: Maximum Observed Plasma Concentration (Cmax) of VX-973 From Day 1 up to Day 30 Part B: Time Taken for VX-973 to Reach Maximum Concentration (tmax) From Day 1 up to Day 85 Part B: Pain Tolerance Threshold (PTT) for the Cold Pressor Test From Day 1 up to Day 53
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (1)
ICON Salt Lake City
🇺🇸Salt Lake City, Utah, United States
ICON Salt Lake City🇺🇸Salt Lake City, Utah, United States